Sintilimab Improves OS in Advanced ESCC, Gastric/GEJ Cancer
Findings from a pair of studies presented at the 2021 European Society for Medical Oncology Annual Meeting showed that adding sintilimab to chemotherapy significantly improved overall survival compared with chemotherapy alone in patients with unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma and those with unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma.
Erdafitinib Plus Cetrelimab Exhibits Encouraging Efficacy in Metastatic Urothelial Cancer
Erdafitinib in combination with cetrelimab displayed clinically meaningful responses in patients with metastatic or locally advanced urothelial carcinoma harboring FGFR alterations.
Nivolumab/Cabozantinib Combo Yields Efficacy Regardless of Prior Nephrectomy in RCC
September 17th 2021Nivolumab and cabozantinib demonstrated significant benefits in progression-free survival and objective response rate for patients with renal cell carcinoma regardless of whether they had a prior nephrectomy.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab plus fluoropyrimidine and platinum-containing chemotherapy as frontline treatment for adult patients with HER2-negative advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma with a PD-L1 combined positive score of 5 or higher.
Brigatinib resulted in a 52% reduction in the risk of disease progression or death and a 56% reduction in the risk of intracranial progression compared with crizotinib in patients with ALK-positive non–small cell lung cancer, according to final data from the phase 3 ALTA-1L trial.
Global Maximum-Tolerated Dose of Mobocertinib Found Tolerable in Japanese Patients With NSCLC
September 16th 2021Mobocertinib displayed a manageable safety profile across 40-mg, 120-mg, and 160-mg dose cohorts in Japanese patients with non–small cell lung cancer, which, when coupled with pharmacokinetic analysis, led to the determination of 160 mg as the maximum tolerated dose and recommended phase 2 dose for further study in this population.
Mobocertinib Shows Improved Responses Vs Real-World Data in Advanced EGFR Exon 20 Insertion+ NSCLC
Mobocertinib, a novel EGFR tyrosine kinase inhibitor, exhibited clinically meaningful activity in patients with non–small cell lung cancer who harbor EGFR exon 20 insertion mutations following frontline platinum-based chemotherapy when compared indirectly with real-world data of patients treated with standard of care.
Linagliptin/Atezolizumab Combo Shows Limited Clinical Activity in Second-Line Gastric/GEJ Cancer
Linagliptin plus atezolizumab was linked with limited responses as a second-line treatment for patients with locally advanced or metastatic gastric or gastroesophageal junction cancer who participated in an arm of the open-label, phase 1b/2 MORPHEUS platform.
Darolutamide Favorably Affects Episodic Memory Vs Enzalutamide in mCRPC
September 16th 2021Treatment with darolutamide was associated with statistically significant benefits in episodic memory by computerized cognitive assessment compared with enzalutamide in patients with metastatic castration-resistant prostate cancer.
ESMO 2021: Oncology Experts Share Game-Changing Data in Breast Cancer, Gynecologic Malignancies
The 2021 ESMO Congress, held as a virtual format for the second consecutive year, is fast approaching and isn’t holding back in terms of pivotal data across malignancies, especially in breast cancer and gynecologic cancers.
Brigatinib Boosts Intracranial PFS and Health-Related QoL in ALK+ NSCLC
October 1st 2020Brigatinib demonstrated sustained improvements in overall and intracranial progression-free survival and health-related quality of life compared with crizotinib in patients with ALK-positive advanced non–small cell lung cancer.
Apalutamide Maintains Health-Related QoL Among Men With Nonmetastatic CRPC
September 25th 2020With more than 4 years of follow-up, the health-related quality of life of men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy was shown to be maintained with the addition of apalutamide.
Dr. Hamilton on the Results of the nextMONARCH Trial in Patients With HR+/HER2- Breast Cancer
September 23rd 2020Erika P. Hamilton, MD, discusses the final overall survival results from the randomized, phase 2 nextMONARCH trial in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Nivolumab/Chemo Improves PFS, Elicits Durable Responses in Gastric/GEJ Cancers
September 21st 2020The addition of nivolumab to chemotherapy resulted in a statistically significant improvement in progression-free survival and elicited higher overall response rates in patients with previously untreated advanced or recurrent gastric and gastroesophageal junction cancer.
Atezolizumab Plus Bevacizumab/Chemo Fails to Significantly Improve PFS in Ovarian Cancer
The addition of atezolizumab to a backbone comprised of bevacizumab and chemotherapy failed to significantly improve progression-free survival in patients with newly diagnosed stage III/IV ovarian cancer.
Dr. Coleman on the Clinical Implications of the innovaTV 204 Trial in Cervical Cancer
September 21st 2020Robert L. Coleman, MD, FACOG, FACS, discusses the clinical implications of the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 trial in women with previously treated recurrent or metastatic cervical cancer.
Study Demonstrates Improved Responses With Molecularly-Guided Therapy in mRCC
September 21st 2020Findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial demonstrated clinical evidence to support the use of molecularly-directed frontline therapy as means to enrich responses in patients with metastatic clear cell renal cell carcinoma.
Cemiplimab Demonstrates Frontline Potential in Advanced PD-L1+ NSCLC
September 21st 2020Cemiplimab-rwlc monotherapy led to a significant improvement in overall survival and progression-free survival versus platinum-doublet chemotherapy as first-line therapy in patients with advanced non–small cell lung cancer with PD-L1 expression on at least 50% of their tumor cell.
Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma
September 21st 2020The feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demonstrated in the phase 1b TRAMUNE trial.